Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378156 | 0.92 | ACHE (0.47) | MAPTLMNATP53THRBGAA | |
| SCHEMBL5388994 | 0.86 | ACHE (0.54) | MAPTLMNATP53THRBGAA | |
| SCHEMBL5424630 | 0.85 | ACHE (0.54) | MAPTLMNATP53THRBGAA | |
| SCHEMBL5395729 | 0.84 | ACHE (0.52) | MAPTLMNATP53THRBGAA | |
| SCHEMBL5383999 | 0.83 | ACHE (0.51) | MAPTLMNATP53THRBGAA | |
| SCHEMBL14428624 | 0.83 | ACHE (0.51) | MAPTLMNATP53THRBGAA | |
| SCHEMBL14428601 | 0.83 | ACHE (0.51) | MAPTLMNATP53THRBGAA | |
| SCHEMBL5383081 | 0.83 | ACHE (0.51) | MAPTLMNATP53THRBGAA | |
| SCHEMBL14503749 | 0.82 | ACHE (0.47) | MAPTLMNAGAAHTT | |
| SCHEMBL5381941 | 0.81 | ACHE (0.47) | MAPTLMNATP53THRBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197533-A1 | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds | DDC, DPP3, AMPD3 | MAPT 2536/4885LMNA 4065/4885TP53 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.